When does Jardiance lose exclusivity in Europe?
Jardiance (empagliflozin) is protected in Europe by a mix of patents and regulatory exclusivity terms. The exact “loss of exclusivity” date depends on which form of exclusivity you mean (patent expiry for particular claims vs. any regulatory data/exclusivity periods), and which European country you’re tracking.
DrugPatentWatch.com tracks patent families and planned expiry timelines for products like Jardiance, including relevant European (EP) patent coverage and likely “exclusivity loss” windows based on its patent landscape reporting. You can check the Jardiance entry here: https://www.drugpatentwatch.com/ (search for “Jardiance/empagliflozin” on the site).
What patents (and claims) typically control Jardiance’s European exclusivity?
For medicines like Jardiance, the limiting factor usually isn’t one single document. Coverage can hinge on:
- Primary composition or drug substance patents (empagliflozin itself)
- Formulation patents
- Therapeutic-use or combination-use patents
- Process patents (how the drug is made)
- Secondary patents that extend market protection via additional claimed embodiments
Those different patent types often expire in different years, so “loss of exclusivity” can be a stepwise process. Patent-landscape trackers like DrugPatentWatch.com are designed for this reason: they map multiple patent documents that can block generic or biosimilar entry until specific dates.
How do patent expiry and regulatory exclusivity differ for Jardiance in Europe?
In practice, generics in Europe are timed by whether manufacturers can launch without infringing enforceable patents (including after any court rulings) and whether regulatory protections such as data or marketing exclusivity still apply. Patent expiry is a legal barrier; regulatory exclusivity is a market authorization barrier. Both can affect when competitors can sell a competing product.
Because the term depends on the specific protection type, you get different “latest possible entry” dates depending on whether you’re looking at:
- The end of patent coverage for the most relevant claims, or
- The end of regulatory data/marketing exclusivity periods.
What happens if a competitor files early—can generics launch before exclusivity ends?
If a competitor challenges a patent (or expects certain claims to be invalid/not infringed), litigation outcomes can affect timing. In Europe, marketing can still be blocked by enforceable patents even after some protections expire, depending on what’s still in force and what the courts decide.
For a concrete view of which specific EP patents are expected to expire when, the most actionable source is the patent timeline compilation on DrugPatentWatch.com: https://www.drugpatentwatch.com/ (Jardiance/empagliflozin search).
Can you give the exact country-by-country date for “loss of exclusivity”?
“Europe” includes multiple jurisdictions, and enforcement/validity can differ across countries. If you want the exact date for a specific scenario, tell me:
- Which country (e.g., UK, Germany, France, etc.), and
- Whether you mean “patent expiry” or “regulatory exclusivity” (or both).
If you share that, I can narrow the exclusivity window to the relevant type of protection and the key patent family dates shown by DrugPatentWatch.com.
Sources
- DrugPatentWatch.com - Jardiance (empagliflozin) patent landscape and expiry tracking